Keith W. Ward, Ph.D.
President and Chief Executive Officer (CEO)
Keith W. Ward, PhD, the Company’s Chief Executive Officer, joined InterveXion in 2019, and brings significant C-level biotech leadership experience to the company. Prior to joining InterveXion, Dr. Ward served as Executive Vice President and Chief Development Officer for Reata Pharmaceuticals, where he led research and development, clinical operations, regulatory affairs, manufacturing, and project management. Before that, Dr. Ward developed ophthalmic pharmaceuticals and medical devices as Global Vice President of Pharmaceutical R&D for Bausch & Lomb. Dr. Ward has also held positions of increasing responsibility within GlaxoSmithKline and SmithKline Beecham Pharmaceuticals. Dr. Ward earned a B.S. in Toxicology with a minor in Chemistry from Northeast Louisiana University and a Ph.D. in Toxicology from The University of North Carolina at Chapel Hill.
Misty Stevens, Ph.D., MBA
Chief Operating Officer
Misty Ward Stevens, PhD, MBA is Chief Operating Officer for InterveXion with experience in protein biochemistry and cell culture, plus entrepreneurship. These skills allow her to conduct and oversee science operations at InterveXion and coordinate activities with commercial laboratories conducting the antibody manufacturing and testing. Furthermore, she has been involved in grant writing and administration, business plan and budget maturity, and patent filings.
W. Brooks Gentry, MD
Chief Medical Officer (CMO)
Professor, Departments of Anesthesiology and Pharmacology & Toxicology and Wilbur D Mills Chair in Alcohol and Drug Abuse Studies, University of Arkansas for Medical Sciences
InterveXion’s Chief Medical Officer is W. Brooks Gentry, MD, who is currently a Professor of Anesthesiology and Pharmacology & Toxicology and former Chair of the Department of Anesthesiology at UAMS. Dr. Gentry brings expertise in clinical trial design for therapeutic biologics, including monoclonal antibodies. He has performed human clinical and basic science research on drugs that affect the central nervous system (brain and spinal cord) since 1991.
S. Michael Owens, Ph.D.
Chief Scientific Officer (CSO)
Retired Professor and Director, Center for Alcohol and Drug Abuse
and Arkansas Research Alliance Fellow, University of Arkansas for Medical Sciences
S. Michael Owens, PhD, the Company’s Chief Scientific Officer, was a Professor of Pharmacology and Toxicology at UAMS until retiring in August 2019. Dr. Owens has expertise in pharmacokinetics, pharmacodynamics and immunopharmacology with extensive experience in vaccine design and the development of therapeutic monoclonal antibodies. He pioneered the research and development of the therapeutic antibodies and vaccines for drug abuse that are the foundation for InterveXion.
Ralph Henry, Ph.D.
Executive Vice President, Corporate Development and Biopharmaceutics
Dr. Henry directed research at the University of Arkansas focused on protein targeting, protein production technologies, and development of antibody-based therapies to treat methamphetamine addiction. As a co-founder of InterveXion and in his role as VP, Dr. Henry brings experience in molecular biology, protein manufacturing technology, and molecular engineering of proteins. Dr. Henry supports interactions with FDA, manufacturing and testing of InterveXion’s protein therapies, and oversight of these therapies for pre-clinical and human clinical trials.
Gerald A. Damerow
Chief Financial Officer
A former Ernst & Young partner, Gerald Damerow, CPA, serves as acting Chief Financial Officer. He is also a retired Associate Director of the UAMS BioVentures business accelerator.